Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

Journal of the National Cancer Institute

Volumn 109, Issue 5, 2017, Pages

  Taieb, Julien ^a   Le Malicot, Karine ^b   Shi, Qian ^c   Lorca, Frédérique Penault ^d   Bouché, Olivier ^e   Tabernero, Josep ^f,g   Mini, Enrico ^h   Goldberg, Richard M ⁱ   Folprecht, Gunnar ^j   Van Laethem, Jean Luc ^k   Sargent, Daniel J ^c   Alberts, Steven R ^l   Emile, Jean Francois ^m   Puig, Pierre Laurent ^n,o,p   Sinicrope, Frank A ^l  

^a University Sorbonne Paris Cite   (France)

^b Federation Francophone de Cancerologie Digestive FFCD Statistical Center   (France)

^c MAYO CLINIC   (United States)

^d CENTRE JEAN PERRIN   (France)

^e SERVICE DE DERMATOLOGIE   (France)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^k ERASME HOSPITAL   (Belgium)

^l MAYO CLINIC CANCER CENTER   (United States)

^m HÔPITAL AMBROISE PARÉ   (France)

ⁿ UNIVERSITÉ PARIS DESCARTES   (France)

^o HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^p INSERMUMR S1147   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROURACIL; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; FOLINIC ACID; KRAS PROTEIN, HUMAN; PLATINUM COMPLEX; PROTEIN P21;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL OUTCOME; CODON; COLON CANCER; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISMATCH REPAIR; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; COLON RESECTION; COLONIC NEOPLASMS; CONTROLLED STUDY; GENETICS; MICROSATELLITE INSTABILITY; MUTATION; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SECONDARY; SURVIVAL RATE; TIME FACTOR; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CETUXIMAB; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 85020653725     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw272     Document Type: Article

References (36)

1. Boyle P, Langman JS. ABC of colorectal cancer: Epidemiology. BMJ. 2000; 321(7264):805-808.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96.
3. Benson AB 3rd, Venook AP, Bekaii-Saab T, et al. Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014;12(7):1028-1059.
4. Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii1-iii9.
5. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol. 2011;22(7):1535-1546.
6. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374-379.
7. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525-532.
8. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371(17): 1609-1618.
9. Blons H, Emile JF, Le Malicot K, et al. Prognostic value of KRAS mutations in stage III colon cancer: Post hoc analysis of the PETACC8 phase III trial data set. Ann Oncol. 2014;25(12):2378-2385.
10. Sinicrope FA, Mahoney MR, Yoon HH, et al. Analysis of molecular markers by anatomic tumor site in stage III colon carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015;21(23): 5294-5304.
11. Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: An assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18(23):6531-6541.
12. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803. Clin Cancer Res. 2012;18(3):890-900.
13. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28(3):466-474.
14. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA. 2012;307(13):1383-1393.
15. Taieb J, Tabernero J, Mini E, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC- 8): An open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(8):862-873.
16. Taieb J, Zaanan A, Le Malicot K, et al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: A post hoc analysis of the PETACC-8 Trial. JAMA Oncol. 2016; in press.
17. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261-268.
18. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer. 2001;85(5):692-696.
19. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21(12):2396-2402.
20. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29(10):1261-1270.
21. Imamura Y, Morikawa T, Liao X, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 2012;18(17):4753-4763.
22. Morikawa T, Kuchiba A, Qian ZR, et al. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol. 2012;19(6):1944-1953.
23. Sinicrope FA, Shi Q, Smyrk TC, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015;148(1):88-99.
24. Yokota T. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem. 2011;12(2): 163-171.
25. Yoon HH, Tougeron D, Shi Q, et al. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014;20(11): 3033-3043.
26. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst. 1998;90(9):675-684.
27. Benedix F, Meyer F, Kube R, et al. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma. Pathol Res Pract. 2012;208(10):592-597.
28. de Cuba EM, Snaebjornsson P, Heideman DA, et al. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers. Int J Cancer. 2016;138(5):1139-1145.
29. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138(6):2088-2100.
30. Kim YH, Kakar S, Cun L, et al. Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps. Int J Cancer. 2008;123(11):2587-2593.
31. De Sousa EMF, Wang X, Jansen M, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5):614-618.
32. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609-618.
33. Bond CE, Umapathy A, Ramsnes I, et al. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers. Int J Cancer. 2012;130(7): 1567-1576.
34. Ogino S, Liao X, Imamura Y, et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013;105(23):1789-1798.
35. Seo AN, Park KU, Choe G, et al. Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients. Tumour Biol. 2015;36(12):9813-9821.
36. Kavuri SM, Jain N, Galimi F, et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 2015;5(8):832-841.